SYN 002
Alternative Names: SYN-002; SYN002 - SynklinoLatest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator Synklino
- Class Antivirals; Chemokines; Immunotoxins; Recombinant fusion proteins
- Mechanism of Action Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cytomegalovirus infections
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for preclinical development in Cytomegalovirus infections in USA (Parenteral)
- 08 Jun 2022 Synklino announces intention to submit IND for Cytomegalovirus infections in the first half of 2023
- 05 Oct 2020 SYN 002 technology has related patent protection in USA, Canada, Europe, Japan and World